Surrozen to Advance Potential Eye Drug into Clinical Development Following FDA Clearance
MT Newswires Live
Yesterday
Surrozen (SRZN) is advancing its eye drug, SZN-8141, into human clinical trials after receiving clearance from the US FDA to treat diabetic macular edema, the company said Friday.
The FDA clearance satisfies the second closing milestone of its March 2025 private placement, providing the company with $95.1 million in gross proceeds, according to a statement.
Surrozen said it expects to use the proceeds from the second closing to support the development of SZN-8141 and SZN-8143, as well as its broader operating activities.
Additionally, the biotechnology company expects to dose the first patient in phase 1b/2a Duet clinical study evaluating SZN-8141 in patients with diabetic macular edema in Q4, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.